<PAGE> 1
Exhibit 99.5
July 27, 2000
Board of Directors
Jones Pharma Incorporated
1945 Craig Road
St. Louis, Missouri 63146
Members of the Board:
We hereby consent to the use of our opinion letter dated July 11, 2000 to the
Board of Directors of Jones Pharma Incorporated ("Jones"), included as Annex C
to the Joint Proxy Statement/Prospectus which forms a part of the Registration
Statement on Form S-4 of King Pharmaceuticals, Inc. relating to the proposed
merger involving Jones and King Pharmeceuticals, Inc., and to the references
therein to such opinion in the section entitled "Opinions of Financial
Advisors--Opinion of Jones' Financial Advisor."
In giving such consent, we do not admit that we come within the category of
persons whose consent is required under Section 7 of the Securities Act of 1933,
as amended, or the rules and regulations of the Securities and Exchange
Commission thereunder, nor do we thereby admit that we are experts with respect
to any part of such Registration Statement within the meaning of the term
"experts" as used in the Securities Act of 1933, as amended, or the rules and
regulations of the Securities and Exchange Commission thereunder.
Chase Securities Inc.
/s/ Drew Quigley
-------------------------------
By: Andrew Quigly
Its: Vice President
